| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 01.07.2005 (6986
dage). |
Ingen historik.
| Branche | | Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900). |
| Sidst opdateret den 24.12.2007 og
angivet som gældende fra 01.01.2008 (6072
dage). |
| Historik | Start | Stop |
|---|
| Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900) | 01.01.2008 | |
| Forskning og udvikling inden for naturvidenskab og teknik (731000) | 01.07.2005 | 31.12.2007 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 01.07.2005 (6986
dage). |
Ingen historik.
| Kontaktoplysninger | | investors@forward-pharma.com. |
| Sidst opdateret den 22.10.2019 og
angivet som gældende fra 22.10.2019 (1760
dage). |
| Historik | Start | Stop |
|---|
| investors@forward-pharma.com | 22.10.2019 | |
| art@forward-pharma.com | 17.09.2015 | 21.10.2019 |
| PMA@forward-pharma.com | 08.05.2012 | 16.09.2015 |
| Historik | Start | Stop |
|---|
| 33444242 | 01.12.2006 | 03.02.2023 |
| Virksomheden har ikke ændret Telefon i sin
levetid. |
Ingen nuværende registrering.
| Navne | | FORWARD PHARMA A/S. |
| Sidst opdateret den 01.07.2005 og
angivet som gældende fra 01.07.2005 (6986
dage). |
Ingen historik.
| Tegningsregel | | Selskabet tegnes (i) af bestyrelsens formand i forening med et bestyrelsesmedlem, (ii) af bestyrelsens formand i forening med et medlem af direktionen eller (iii) af den samlede bestyrelse. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 14.11.2014 (3563
dage). |
| Fortolkning
(3 tegningsmuligheder)
| | formanden + 1 bestyrelsesmedlem |
| formanden + 1 direktionsmedlem |
| bestyrelsen |
Ingen historik.
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33771231
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision): We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the ”Auditor’s responsibilities for the audit of the Financial Statements” section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2023 and of the results of the Company´s operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act. We have audited the Financial Statements of Forward Pharma A/S for the financial year 1 January - 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies (”the Financial Statements”).
Udtalelse om ledelsesberetningen (revision):Management is responsible for Management’s Review. Our opinion on the Financial Statements døs not cover Management’s Review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the Financial Statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act. Based on the work we have performed, in our view, Management’s Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management’s Review.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Hjemmeside | | www.forward-pharma.com. |
| Sidst opdateret den 03.02.2023 og
angivet som gældende fra 03.02.2023 (560
dage). |
Ingen historik.
LoginOpret gratis brugere-conomic integration